Torrent Pharma has approved the issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs) aggregating upto Rs 12,500 crore in one or more tranches on private placement basis.Powered by Capital Market - Live News

Torrent Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 January 2026.Powered by Capital Market - Live News

Torrent Pharmaceuticals announced that commercial paper of Rs 200 crore has been redeemed and repaid by the company on maturity date i.e. 23 December 2025. Powered by Capital Market - Live News

Torrent Pharmaceuticals announced that NSE Sustainability Ratings and Analytics, a SEBI registered ESG Rating Provider, has independently assigned the Environmental, Social, and Governance (ESG) Rating of 70 to the Company.Powered by Capital Market - Live News

Net profit of Torrent Pharmaceuticals rose 30.46% to Rs 591.00 crore in the quarter ended September 2025 as against Rs 453.00 crore during the previous quarter ended September 2024. Sales rose 14.66% to Rs 3246.00 crore in the quarter ended September 2025 as against Rs 2831.00 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales3246.002831.00 15 OPM %33.3633.17 - PBDT1008.00859.00 17 PBT804.00661.00 22 NP591.00453.00 30 Powered by Capital Market - Live News